Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

particularly non-small cell lung cancer (NSCLC) and pancreatic cancer, according to results from a phase II study. Among 158 evaluable patients with 10 tumor types, 30% had an overall response ...

The findings revealed that tumors with higher levels of RAS ... response to KRASG12C inhibitors in KRASG12C-mutant non–small cell lung cancer, Clinical Cancer Research (2025).

Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, has been awarded $2.7 million in seed funding from ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...